A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The study's overall objectives are to evaluate the safety of anakinra in combination with
standard chemotherapy regimens in patients with pancreatic ductal adenocarinoma, as well as
to collect preliminary immune modulation and clinical activity information, overall survival,
and serious adverse events related to the study drug.
Phase:
Phase 1
Details
Lead Sponsor:
Baylor Research Institute
Treatments:
Fluorouracil Interleukin 1 Receptor Antagonist Protein Irinotecan Oxaliplatin